HTR6 and early-onset autosomal dominant Alzheimer disease: The global results of the primary screening performed for the 1,3,5-triazine piperazines have confirmed promising properties of this new group in search for novel chemical families of 5-HT6R agents with therapeutic perspective as a drug against memory and cognitive impairment, i.e., Alzheimer’s disease and dementia.